NEW YORK, Oct. 03, 2019 (GLOBE NEWSWIRE) -- Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Nektar Therapeutics (Nasdaq: NKTR) between February 15, 2019 and August 8, 2019, inclusive (the “Class Period”).

If you wish to serve as lead plaintiff, you must move the Court no later than October 18, 2019. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Your ability to obtain a recovery is not dependent upon being a lead plaintiff. If you wish to join the case go: http://zhanginvestorlaw.com/join-action-form/?slug=nektar-therapeutics&id=1997 or to discuss your rights or interests regarding this class action, please contact Sophie Zhang, Esq. or Spencer Lee toll-free at 800-991-3756 or email info@zhanginvestorlaw.com, slee@zhanginvestorlaw.com for information on the class action.

如果您想加入这个集体诉讼案，请在这里提交您的信息。http://zhanginvestorlaw.com/join-action-form/?slug=nektar-therapeutics&id=1997.

According to the case, defendants made false and/or misleading statements and/or failed to disclose that (i) that the Company did not comply with current good manufacturing practices; (ii) as a result, batches of NKTR-214 were not produced consistently and differed meaningfully; (iii) clinical results from PIVOT-02 differed based on the batch of NKTR-214 used in the study; and (iv) as a result, the PIVOT-02 study did not produce statistically significant results to support a finding of clinical benefit.

A class has not been certified.  You may retain counsel of your choice.  You may take no action at this time and be an absent class member. Your ability to obtain a recovery is not dependent upon being a lead plaintiff.

Zhang Investor Law represents investors worldwide.  Attorney Advertising.  Prior results do not guarantee similar outcomes.

Zhang Investor Law P.C.
99 Wall Street, Suite 232
New York, New York 10005
info@zhanginvestorlaw.com
tel: (800) 991-3756

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.